Success Metrics

Clinical Success Rate

80.0%

Based on 8 completed trials

Completion Rate

80%(8/10)

Active Trials

1(8%)

Results Posted

50%(4 trials)

Terminated

2(15%)

Phase Distribution

Ph phase_2

38%

Ph not_applicable

15%

Ph early_phase_1

Ph phase_3

Ph phase_4

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Early Phase 1First-in-human

1(7.7%)

Phase 2Efficacy & side effects

5(38.5%)

Phase 3Large-scale testing

1(7.7%)

Phase 4Post-market surveillance

4(30.8%)

N/ANon-phased studies

2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(8)

Terminated(2)

Other(2)

Detailed Status

Completed8

Terminated2

unknown2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (7.7%)

Phase 25 (38.5%)

Phase 31 (7.7%)

Phase 44 (30.8%)

N/A2 (15.4%)

Trials by Status

completed862%

terminated215%

unknown215%

active_not_recruiting18%

Recent Activity

1 active trials

Showing 5 of 13

completedphase_4

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

NCT04108104

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT06751290Phase 4

The Use of Cyproheptadine in Pediatric Feeding Disorders

Completed

NCT02418949Not Applicable

Altering Activation Patterns Post-stroke

Completed

NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting

NCT06175273Phase 2

Pediatric Oncology Nutrition Intervention Trial

Completed

NCT04108104Phase 2

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

Completed

NCT04979221Phase 3

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Unknown

NCT02568007Phase 4

Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

Terminated

NCT01675050Phase 2

A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

Terminated

NCT01688570Early Phase 1

Mechanisms of Neuromuscular Fatigue Post Stroke

Completed

NCT01538693Not Applicable

Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury

Completed

NCT01940978Phase 4

A Study of Combination Therapy in Children With ADHD

Completed

NCT01076283Phase 2

A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking

Completed

NCT01314989Phase 4

Cyproheptadine as an Appetite Stimulant

Unknown

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13